Article Data

  • Views 1938
  • Dowloads 168

Original Research

Open Access

RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BENZOCAINE WIPES IN SUBJECTS WITH PREMATURE EJACULATION

  • Ridwan Shabsigh1,2
  • Michael A. Perelman2
  • Robert H. Getzenberg3
  • Allison Grant4
  • Jed Kaminetsky5

1SBH Health System, Weill-Cornell Medical School and CUNY School of Medicine, New York, NY, USA

2Department of Psychiatry, Weill-Cornell Medical College, New York, NY, USA

3Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA

4Albert Einstein College of Medicine, New York, NY, USA

5Manhattan Medical Research, New York, NY, USA

DOI: 10.22374/jomh.v15i3.156 Vol.15,Issue 3,July 2019 pp.80-88

Published: 02 July 2019

*Corresponding Author(s): Ridwan Shabsigh E-mail: rshabsigh@gmail.com

PDF (582.62 kB)

Abstract

Aim

This study investigated the efficacy and safety of benzocaine wipes (PREBOOST) applied to the penis prior to intercourse for the treatment of men with premature ejaculation.

Materials and methods

The study utilized the local anesthetic benzocaine, in the form of wipes, for topical application to the glans penis prior to sexual intercourse. The design included three phases: screening and baseline, blinded randomized controlled, and an open-label phase with crossover of the placebo group to open-label active treatment. The two co-primary efficacy measures were the intravaginal ejaculatory latency time (IELT) measured by stopwatch, and the patient-reported outcome measured by the Index of Premature Ejaculation (IPE). Additional efficacy evaluation included a responder analysis using a predetermined 120s improvement in IELT as a responder threshold. Safety evaluation included patient-reported events along with a physical examination.

Results

The treatment phase showed a statistically significant increase from the baseline, in the treatment group (mean 165s) compared with the placebo group (mean 110s), P<0.007. After the second month of use, the treatment group had a mean IELT of 329.70s (±21.37 SE) in comparison to the placebo group which had a mean IELT of 110.10s (±9.90 SE) (P=0.001). The open-label phase showed further increase in IELT in the treatment group and a statistically significant increase in IELT in the placebo/crossover group. Using the IPE, the men in the treatment group reported significantly higher sexual satisfaction (P=0.047) and greater improvement in distress (P=0.020) with a trend toward improve-ment in the ejaculatory control domain scores (P=0.093). The responder analysis showed a statisti-cally significant response to the use of benzocaine versus placebo, attesting an IELT increase that was clinically meaningful. Benzocaine wipes were well tolerated by subjects and partners.

Conclusion

This randomized, placebo controlled clinical trial with crossover design showed that benzocaine wipes applied topically to the penis prior to sexual intercourse had a statistically significant prolongation of time to ejaculation, a clinically meaningful benefit, in the treatment of premature ejaculation. Furthermore, benzocaine wipes were well tolerated by the subjects and no evidence of transference to their female partners.

Keywords

premature ejaculation, benzocaine, PREBOOST, placebo-controlled, wipes, sexual satisfaction

Cite and Share

Ridwan Shabsigh,Michael A. Perelman,Robert H. Getzenberg,Allison Grant,Jed Kaminetsky. RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BENZOCAINE WIPES IN SUBJECTS WITH PREMATURE EJACULATION. Journal of Men's Health. 2019. 15(3);80-88.

References

1. Laumann EO, Paik A, Rosen C. Sexual dysfunc-tion in the United States: Prevalence and predic-tors. JAMA 1999;281:537.

2. American Psychiatric Association. Diagnostic & Statistical Manual of Mental Disorders. 4th ed.(DSM-IV). Washington, DC: American Psychiatric Association; 1994.

3. Vickers MA. The forgotten dysfunction: A phar-macological approach to premature ejaculation. In: Morales A, editor. Erectile dysfunction—Issues in current pharmacology. London: Martin Dunitz; 1998. p. 253.

4. Reading A, Weist W. An analysis of self-reported sexual behaviour in a sample of normal males. Arch Sex Behav 1984;13:69–83.

5. De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Clinical follow-up of cou-ples treated for sexual dysfunction. Arch Sex Behav 1985;14:467–89.

6. Beretta G, Chelo E, Fanciullacci F, Zanollo A. Effect of an alpha-blocking agent (phenoxyben-zamine) in the management of premature ejacula-tion. Acta Eur Fertil 1986;17:43–5.

7. Girgis SM, El-Haggar S, El-Hermouzy S. A dou-ble-blind trial of clomipramine in premature ejac-ulation. Andrologica 1982;14:364–8.

8. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study. J Urol 1996;156: 1631–2.

9. McMahon CG. Treatment of premature ejacula-tion with sertraline hydrochloride. Int J Impot Res 1998;10:181–4.

 10. McMahon CG, Touma K, Johnston H. Treatment of premature ejaculation with paroxetine hydro-chloride. Int J Impot Res 1998;10 (Suppl 3):S38.

 11. Vignoli GC. Premature ejaculation: New electro-physiologic approach. Urology 1978;11:81–2.

 12. Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ, Choi HK. Penile sensitivity in patients with primary premature ejaculation. J Urol 1996;156: 979–81.

 13. Xin ZC, Choi YD, Rha KH, Choi HK. Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol 1997;158: 451–5.

 14. Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L. Development and validation of a new questionnaire to assess sexual satisfac-tion, control, and distress associated with prema-ture ejaculation. J Sex Med 2006 May;3(3):465–75. PubMed PMID: 16681472

Abstracted / indexed in

Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.

Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.

CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.

Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.

Submission Turnaround Time

Conferences

    Top